US5969145A
(en)
*
|
1996-08-30 |
1999-10-19 |
Novartis Ag |
Process for the production of epothilones and intermediate products within the process
|
WO1998022461A1
(de)
*
|
1996-11-18 |
1998-05-28 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
Epothilone c, d, e und f, deren herstellung und deren verwendung als cytostatische mittel bzw. als pflanzenschutzmittel
|
US6204388B1
(en)
|
1996-12-03 |
2001-03-20 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
US6867305B2
(en)
|
1996-12-03 |
2005-03-15 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
JP4579351B2
(ja)
|
1996-12-03 |
2010-11-10 |
スローン−ケッタリング インスティトュート フォア キャンサー リサーチ |
エポチロンの合成とその中間体及びその類似物並びにその使用
|
US20050043376A1
(en)
*
|
1996-12-03 |
2005-02-24 |
Danishefsky Samuel J. |
Synthesis of epothilones, intermediates thereto, analogues and uses thereof
|
US6441186B1
(en)
|
1996-12-13 |
2002-08-27 |
The Scripps Research Institute |
Epothilone analogs
|
US6660758B1
(en)
*
|
1996-12-13 |
2003-12-09 |
The Scripps Research Institute |
Epothilone analogs
|
US6380394B1
(en)
|
1996-12-13 |
2002-04-30 |
The Scripps Research Institute |
Epothilone analogs
|
US6605599B1
(en)
|
1997-07-08 |
2003-08-12 |
Bristol-Myers Squibb Company |
Epothilone derivatives
|
DE59814067D1
(de)
|
1997-08-09 |
2007-09-06 |
Bayer Schering Pharma Ag |
Neue epothilon-derivate, verfahren zu deren herstellung und ihre pharmazeutische verwendung
|
US6365749B1
(en)
*
|
1997-12-04 |
2002-04-02 |
Bristol-Myers Squibb Company |
Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
|
US6683100B2
(en)
|
1999-01-19 |
2004-01-27 |
Novartis Ag |
Organic compounds
|
US6194181B1
(en)
|
1998-02-19 |
2001-02-27 |
Novartis Ag |
Fermentative preparation process for and crystal forms of cytostatics
|
FR2775187B1
(fr)
|
1998-02-25 |
2003-02-21 |
Novartis Ag |
Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
|
US6302838B1
(en)
|
1998-02-25 |
2001-10-16 |
Novartis Ag |
Cancer treatment with epothilones
|
US6399638B1
(en)
*
|
1998-04-21 |
2002-06-04 |
Bristol-Myers Squibb Company |
12,13-modified epothilone derivatives
|
US6498257B1
(en)
*
|
1998-04-21 |
2002-12-24 |
Bristol-Myers Squibb Company |
2,3-olefinic epothilone derivatives
|
DE19826988A1
(de)
*
|
1998-06-18 |
1999-12-23 |
Biotechnolog Forschung Gmbh |
Epothilon-Nebenkomponenten
|
CA2350189A1
(en)
|
1998-11-20 |
2000-06-02 |
Kosan Biosciences, Inc. |
Recombinant methods and materials for producing epothilone and epothilone derivatives
|
US6410301B1
(en)
|
1998-11-20 |
2002-06-25 |
Kosan Biosciences, Inc. |
Myxococcus host cells for the production of epothilones
|
CN1122668C
(zh)
|
1998-12-22 |
2003-10-01 |
诺瓦提斯公司 |
环氧噻酮衍生物,其制备方法及其药物组合物
|
US6780620B1
(en)
*
|
1998-12-23 |
2004-08-24 |
Bristol-Myers Squibb Company |
Microbial transformation method for the preparation of an epothilone
|
KR20010094763A
(ko)
*
|
1999-02-11 |
2001-11-01 |
에바-마리아 시마-메이어, 얼설라 멜져, 마거, 하르트만 |
에포틸론 유도체, 그 제조방법 및 제약적 용도
|
US7125875B2
(en)
|
1999-04-15 |
2006-10-24 |
Bristol-Myers Squibb Company |
Cyclic protein tyrosine kinase inhibitors
|
ES2391550T3
(es)
|
1999-04-15 |
2012-11-27 |
Bristol-Myers Squibb Company |
Inhibidores cíclicos de la proteína tirosina quinasa
|
US7125893B1
(en)
|
1999-04-30 |
2006-10-24 |
Schering Ag |
6-alkenyl-, 6-alkinyl- and 6-epoxy-epothilone derivatives, process for their production, and their use in pharmaceutical preparations
|
EP1229934B1
(en)
|
1999-10-01 |
2014-03-05 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
US6518421B1
(en)
*
|
2000-03-20 |
2003-02-11 |
Bristol-Myers Squibb Company |
Process for the preparation of epothilone analogs
|
DE10020899A1
(de)
*
|
2000-04-20 |
2001-10-25 |
Schering Ag |
9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
|
US6489314B1
(en)
|
2001-04-03 |
2002-12-03 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
AU2001266583A1
(en)
*
|
2000-05-26 |
2001-12-11 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
UA75365C2
(en)
|
2000-08-16 |
2006-04-17 |
Bristol Myers Squibb Co |
Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
|
WO2002030356A2
(en)
|
2000-10-13 |
2002-04-18 |
The University Of Mississipi |
Synthesis of epothilones and relates analogs
|
IL156578A0
(en)
*
|
2001-01-25 |
2004-01-04 |
Bristol Myers Squibb Co |
A method for formulating an epothilone analog for pharmaceutical use and pharmaceutical preparations including an epothilone analog
|
NZ526871A
(en)
|
2001-01-25 |
2006-01-27 |
Bristol Myers Squibb Co |
Pharmaceutical dosage forms of epothilones for oral administration
|
HU229349B1
(en)
|
2001-01-25 |
2013-11-28 |
Bristol Myers Squibb Co |
Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer
|
PL367260A1
(en)
*
|
2001-01-25 |
2005-02-21 |
Bristol-Myers Squibb Company |
Parenteral formulation containing epothilone analogs
|
US6893859B2
(en)
|
2001-02-13 |
2005-05-17 |
Kosan Biosciences, Inc. |
Epothilone derivatives and methods for making and using the same
|
BR0207316A
(pt)
|
2001-02-20 |
2004-02-10 |
Bristol Myers Squibb Co |
Derivados de epotilona para o tratamento de tumores refratários
|
RU2003128311A
(ru)
*
|
2001-02-20 |
2005-03-10 |
Бристол-Маерс Сквибб Компани (Us) |
Способ лечения резистентных опухолей с применением аналогов эпотилона
|
ATE325201T1
(de)
|
2001-02-27 |
2006-06-15 |
Biotechnolog Forschung Gmbh |
Abbau von epothilonen und ethynyl substituierte epothilone
|
CZ305799B6
(cs)
*
|
2001-03-14 |
2016-03-23 |
Bristol-Myers Squibb Company |
Kombinace analogů epothilonu a chemoterapeutických činidel pro léčení proliferačních nemocí
|
EP1392664A4
(en)
|
2001-06-01 |
2005-01-26 |
Bristol Myers Squibb Co |
EPOTHILONE DERIVATIVES
|
TWI315982B
(en)
|
2001-07-19 |
2009-10-21 |
Novartis Ag |
Combinations comprising epothilones and pharmaceutical uses thereof
|
PL369670A1
(en)
|
2002-01-14 |
2005-05-02 |
Novartis Ag |
Combinations comprising epothilones and anti-metabolites
|
EP1340498A1
(en)
*
|
2002-03-01 |
2003-09-03 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of brain diseases associated with proliferative processes
|
WO2003077903A1
(en)
*
|
2002-03-12 |
2003-09-25 |
Bristol-Myers Squibb Company |
C12-cyano epothilone derivatives
|
ES2337134T3
(es)
|
2002-03-12 |
2010-04-21 |
Bristol-Myers Squibb Company |
Derivados de c3-ciano-epotilona.
|
TW200403994A
(en)
|
2002-04-04 |
2004-03-16 |
Bristol Myers Squibb Co |
Oral administration of EPOTHILONES
|
TW200400191A
(en)
*
|
2002-05-15 |
2004-01-01 |
Bristol Myers Squibb Co |
Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
AU2003243561A1
(en)
|
2002-06-14 |
2003-12-31 |
Bristol-Myers Squibb Company |
Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
|
DE10232094A1
(de)
*
|
2002-07-15 |
2004-02-05 |
GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) |
5-Thiaepothilone und 15-disubstituierte Epothilone
|
US7649006B2
(en)
|
2002-08-23 |
2010-01-19 |
Sloan-Kettering Institute For Cancer Research |
Synthesis of epothilones, intermediates thereto and analogues thereof
|
DE60330407D1
(de)
*
|
2002-08-23 |
2010-01-14 |
Sloan Kettering Inst Cancer |
Synthese von Epothilonen, Zwischenprodukte davon, Analoga und ihre Verwendung
|
EP2287168B1
(en)
|
2002-09-23 |
2013-02-13 |
Bristol-Myers Squibb Company |
Methods for the preparation, isolation and purification of epothilone B, and X-ray crystal structures of epothilone B
|
EP1553939A1
(en)
*
|
2002-10-11 |
2005-07-20 |
Dana-Farber Cancer Institute, Inc. |
Epothilone derivatives for the treatment of multiple myeloma
|
AU2003302084A1
(en)
|
2002-11-15 |
2004-06-15 |
Bristol-Myers Squibb Company |
Open chain prolyl urea-related modulators of androgen receptor function
|
WO2004048372A1
(en)
*
|
2002-11-28 |
2004-06-10 |
Morphochem Ag Komb Chemie |
Thia-epothilone derivatives for the treatment of cancer
|
BR0317150A
(pt)
*
|
2002-12-09 |
2005-11-01 |
Novartis Ag |
Estabilizadores de microtúbulos em stents para o tratamento de estenose
|
GB0230024D0
(en)
*
|
2002-12-23 |
2003-01-29 |
Novartis Ag |
Organic compounds
|
CN100359014C
(zh)
*
|
2003-01-28 |
2008-01-02 |
北京华昊中天生物技术有限公司 |
一类新型埃坡霉素化合物及其制备方法和用途
|
EP1594854B1
(en)
|
2003-02-06 |
2010-09-01 |
Bristol-Myers Squibb Company |
Thiazolyl-based compounds useful as kinase inhibitors
|
GB0305928D0
(en)
*
|
2003-03-14 |
2003-04-23 |
Novartis Ag |
Organic compounds
|
AU2008200555C1
(en)
*
|
2003-03-14 |
2011-12-15 |
Novartis Ag |
Treatment of proliferative diseases with epothilone derivatives and radiation
|
US7371759B2
(en)
|
2003-09-25 |
2008-05-13 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
DE10344882A1
(de)
*
|
2003-09-26 |
2005-04-21 |
Morphochem Ag Komb Chemie |
Neue Makrocyclen zur Behandlung von Krebserkrankungen
|
US20050171167A1
(en)
*
|
2003-11-04 |
2005-08-04 |
Haby Thomas A. |
Process and formulation containing epothilones and analogs thereof
|
WO2005054429A2
(en)
*
|
2003-11-19 |
2005-06-16 |
The University Of Mississippi |
Synthesis of the c1-c6 keto-acid synthon of the epothilones
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
EP1559447A1
(en)
*
|
2004-01-30 |
2005-08-03 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
US20090004277A1
(en)
*
|
2004-05-18 |
2009-01-01 |
Franchini Miriam K |
Nanoparticle dispersion containing lactam compound
|
US7173031B2
(en)
|
2004-06-28 |
2007-02-06 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
WO2006017761A2
(en)
*
|
2004-08-05 |
2006-02-16 |
Emory University |
Epothilone analogues as therapeutic agents
|
EP1640004A1
(en)
*
|
2004-09-24 |
2006-03-29 |
Schering Aktiengesellschaft |
Use of epothilones in the treatment of bone metastases and bone tumors or cancers
|
US8232244B2
(en)
|
2007-02-08 |
2012-07-31 |
The Board Of Trustees Of The University Of Illinois |
Compositions and methods to prevent cancer with cupredoxins
|
EP1824458A1
(en)
*
|
2004-11-18 |
2007-08-29 |
Bristol-Myers Squibb Company |
Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
|
DK1817013T3
(da)
|
2004-11-18 |
2008-10-13 |
Brystol Myers Squibb Company |
Enterisk coatet kugle omfattende Ixabepilon
|
US20060121511A1
(en)
|
2004-11-30 |
2006-06-08 |
Hyerim Lee |
Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
|
EP1674098A1
(en)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
|
CA2597647A1
(en)
|
2005-02-11 |
2007-08-02 |
University Of Southern California |
Method of expressing proteins with disulfide bridges
|
CA2607940C
(en)
|
2005-05-18 |
2009-12-15 |
Aegera Therapeutics Inc. |
Bir domain binding compounds
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US20110104664A1
(en)
|
2006-03-31 |
2011-05-05 |
Bristol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to micortubule-stabilizing agents
|
WO2007130501A2
(en)
*
|
2006-05-01 |
2007-11-15 |
University Of Southern California |
Combination therapy for treatment of cancer
|
SG10201407457UA
(en)
|
2006-05-16 |
2014-12-30 |
Pharmascience Inc |
Iap bir domain binding compounds
|
JP2010511408A
(ja)
|
2006-12-04 |
2010-04-15 |
ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ |
癌をCpGリッチDNAおよびキュプレドキシンで治療するための組成物および方法
|
CN101754969A
(zh)
|
2007-05-25 |
2010-06-23 |
百时美施贵宝公司 |
制备埃坡霉素化合物和类似物的方法
|
US20090076099A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched ixabepilone
|
EP2065054A1
(en)
|
2007-11-29 |
2009-06-03 |
Bayer Schering Pharma Aktiengesellschaft |
Combinations comprising a prostaglandin and uses thereof
|
EP2070521A1
(en)
|
2007-12-10 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Surface-modified nanoparticles
|
DE102007059752A1
(de)
|
2007-12-10 |
2009-06-18 |
Bayer Schering Pharma Aktiengesellschaft |
Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
|
CN101909693A
(zh)
*
|
2008-01-08 |
2010-12-08 |
百时美施贵宝公司 |
用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
|
SI2276485T1
(sl)
*
|
2008-04-24 |
2014-10-30 |
Bristol-Myers Squibb Company |
Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo
|
WO2010056901A2
(en)
|
2008-11-13 |
2010-05-20 |
University Of Southern California |
Method of expressing proteins with disulfide bridges with enhanced yields and activity
|
EP2210584A1
(en)
|
2009-01-27 |
2010-07-28 |
Bayer Schering Pharma Aktiengesellschaft |
Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
|
JP4500951B1
(ja)
*
|
2009-08-07 |
2010-07-14 |
学校法人神戸学院 |
Dna合成酵素阻害剤
|
WO2011049625A1
(en)
|
2009-10-20 |
2011-04-28 |
Mansour Samadpour |
Method for aflatoxin screening of products
|
KR101821768B1
(ko)
|
2009-11-05 |
2018-01-24 |
리젠 파마슈티컬스 소시에떼 아노님 |
신규한 벤조피란 키나제 조절제
|
MX340870B
(es)
|
2010-02-12 |
2016-07-27 |
Pharmascience Inc |
Compuestos de unión del dominio de repetición de inhibidores de proteínas de apoptosis de baculovirus.
|
CA3084173A1
(en)
|
2010-05-17 |
2011-11-24 |
Rhizen Pharmaceuticals Sa |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued_-3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
|
EP2571525A4
(en)
|
2010-05-18 |
2016-04-27 |
Cerulean Pharma Inc |
Compositions and methods for treating autoimmune and other diseases
|
JP2013527239A
(ja)
|
2010-06-01 |
2013-06-27 |
プラス・ケミカルス・エスアー |
イクサベピロンの固体形
|
CN101906099A
(zh)
*
|
2010-07-16 |
2010-12-08 |
泰州市今朝伟业精细化工有限公司 |
一种埃博霉素d-内酰胺衍生物化学合成方法
|
AU2012207142B2
(en)
|
2011-01-20 |
2017-04-27 |
Board Of Regents, The University Of Texas System |
MRI markers, delivery and extraction systems, and methods of manufacture and use thereof
|
JP2014511849A
(ja)
*
|
2011-04-01 |
2014-05-19 |
ザ リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク |
安定化された酸増幅剤
|
WO2012135278A2
(en)
*
|
2011-04-01 |
2012-10-04 |
The Research Foundation Of State University Of New York |
Olefin-triggered acid amplifiers
|
MY168757A
(en)
|
2011-05-04 |
2018-12-04 |
Rhizen Pharmaceuticals S A |
Novel compounds as modulators of protein kinases
|
US8809562B2
(en)
|
2011-06-06 |
2014-08-19 |
Chevron Phillips Chemical Company Lp |
Use of metallocene compounds for cancer treatment
|
BR112013031819B1
(pt)
|
2011-06-10 |
2022-05-03 |
Mersana Therapeutics, Inc |
Suporte polimérico, composição farmacêutica, composto, e, uso do suporte
|
CN102863474A
(zh)
|
2011-07-09 |
2013-01-09 |
陈小平 |
一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
|
WO2013008091A1
(en)
*
|
2011-07-13 |
2013-01-17 |
Xellia Pharmaceuticals Aps |
Manufacturing of epothilone derivatives and the use thereof
|
EP2567825B1
(en)
|
2011-09-12 |
2014-04-02 |
Agfa-Gevaert |
Colour laser marking methods of security document precursors
|
CN102993239A
(zh)
|
2011-09-19 |
2013-03-27 |
陈小平 |
离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
|
US9717803B2
(en)
|
2011-12-23 |
2017-08-01 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
EP2831073B1
(en)
|
2012-03-30 |
2020-12-09 |
Rhizen Pharmaceuticals S.A. |
Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of c-met protein kinases
|
EP2872894B1
(en)
|
2012-07-13 |
2019-04-17 |
Innate Pharma |
Screening of conjugated antibodies
|
WO2014072482A1
(en)
|
2012-11-09 |
2014-05-15 |
Innate Pharma |
Recognition tags for tgase-mediated conjugation
|
CN104768962B
(zh)
|
2012-11-17 |
2017-04-05 |
北京市丰硕维康技术开发有限责任公司 |
离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
JP6334553B2
(ja)
|
2012-12-10 |
2018-05-30 |
メルサナ セラピューティクス,インコーポレイティド |
タンパク質−高分子−薬剤コンジュゲート
|
US9872918B2
(en)
|
2012-12-12 |
2018-01-23 |
Mersana Therapeutics, Inc. |
Hydroxyl-polymer-drug-protein conjugates
|
TWI520956B
(zh)
*
|
2013-03-08 |
2016-02-11 |
台灣神隆股份有限公司 |
伊莎匹隆及其中間體之製備方法
|
WO2014144715A1
(en)
|
2013-03-15 |
2014-09-18 |
Memorial Sloan-Kettering Cancer Center |
Hsp90-targeted cardiac imaging and therapy
|
EP2968582B1
(en)
|
2013-03-15 |
2020-07-01 |
Innate Pharma |
Solid phase tgase-mediated conjugation of antibodies
|
KR20160018534A
(ko)
|
2013-06-11 |
2016-02-17 |
바이엘 파마 악티엔게젤샤프트 |
Mps-1 키나제 억제제 및 유사분열 억제제를 포함하는 암의 치료를 위한 조합물
|
EP3010547B1
(en)
|
2013-06-20 |
2021-04-21 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
EP3010548A1
(en)
|
2013-06-21 |
2016-04-27 |
Innate Pharma |
Enzymatic conjugation of polypeptides
|
AU2014331645C1
(en)
|
2013-10-11 |
2020-06-11 |
Asana Biosciences, Llc |
Protein-polymer-drug conjugates
|
BR112016007736B1
(pt)
|
2013-10-11 |
2022-09-27 |
Mersana Therapeutics, Inc |
Armação polimérica, e, composição farmacêutica
|
US10341459B2
(en)
|
2015-09-18 |
2019-07-02 |
International Business Machines Corporation |
Personalized content and services based on profile information
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
US11617799B2
(en)
|
2016-06-27 |
2023-04-04 |
Tagworks Pharmaceuticals B.V. |
Cleavable tetrazine used in bio-orthogonal drug activation
|
US11135307B2
(en)
|
2016-11-23 |
2021-10-05 |
Mersana Therapeutics, Inc. |
Peptide-containing linkers for antibody-drug conjugates
|
WO2018209239A1
(en)
|
2017-05-11 |
2018-11-15 |
Massachusetts Institute Of Technology |
Potent agelastatin derivatives as modulators for cancer invasion and metastasis
|
CN111315414A
(zh)
|
2017-06-22 |
2020-06-19 |
梅尔莎纳医疗公司 |
产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
WO2019092148A1
(en)
|
2017-11-10 |
2019-05-16 |
Innate Pharma |
Antibodies with functionalized glutamine residues
|
DK3788032T3
(da)
|
2018-05-04 |
2024-04-15 |
Tagworks Pharmaceuticals B V |
Forbindelser omfattende en linker til øgning af transcyklooctenstabilitet
|
EP3787691A1
(en)
|
2018-05-04 |
2021-03-10 |
Tagworks Pharmaceuticals B.V. |
Tetrazines for high click conjugation yield in vivo and high click release yield
|
MX2021004906A
(es)
|
2018-10-29 |
2021-09-10 |
Mersana Therapeutics Inc |
Conjugados de anticuerpo modificado con cisteína-fármaco con enlazadores que contienen péptidos.
|
WO2020247054A1
(en)
|
2019-06-05 |
2020-12-10 |
Massachusetts Institute Of Technology |
Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
|
US20230121556A1
(en)
|
2019-06-17 |
2023-04-20 |
Tagworks Pharmaceuticals B.V. |
Compounds for fast and efficient click release
|
IL289094A
(en)
|
2019-06-17 |
2022-02-01 |
Tagworks Pharmaceuticals B V |
Tetrazines for increasing the speed and yield of the "click release" reaction
|
WO2021142202A1
(en)
|
2020-01-10 |
2021-07-15 |
R-Pharm Us Operating Llc |
Compositions of ixabepilone
|
WO2023031445A2
(en)
|
2021-09-06 |
2023-03-09 |
Veraxa Biotech Gmbh |
Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
|
AU2022395626A1
(en)
|
2021-11-25 |
2024-05-30 |
Veraxa Biotech Gmbh |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
EP4186529A1
(en)
|
2021-11-25 |
2023-05-31 |
Veraxa Biotech GmbH |
Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
|
AU2022404647A1
(en)
|
2021-12-08 |
2024-06-13 |
European Molecular Biology Laboratory |
Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
|
DK4314031T3
(da)
|
2022-02-15 |
2024-06-17 |
Tagworks Pharmaceuticals B V |
Maskeret il12-protein
|
WO2024013724A1
(en)
|
2022-07-15 |
2024-01-18 |
Pheon Therapeutics Ltd |
Antibody-drug conjugates
|
WO2024080872A1
(en)
|
2022-10-12 |
2024-04-18 |
Tagworks Pharmaceuticals B.V. |
Strained bicyclononenes
|